General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

filing / Aug 12, 2026 / receipt

● costs of outside consultants, including their fees, stock-based compensation and related travel expenses; ● costs of laboratory supplies and acquiring, developing and manufacturing preclinical and clinical trial materials; ● expenses related to compliance with regulatory requirements; and ● facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of fa

filing / Aug 12, 2026 / receipt

● our headcount growth and associated costs as we expand our business operations and our research and development activities; and

filing / Aug 12, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may affect our ability to generate revenue, attain or maintain profitability, or commercialize our product candidates.

filing / Aug 12, 2026 / receipt

If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and product candidates outside of the United States, which could limit our growth potential and increase our development costs.

filing / Aug 12, 2026 / receipt

A primary trend in the healthcare industry in the United States and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.

filing / Aug 12, 2026 / receipt

General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

filing / May 13, 2026 / receipt

● costs of outside consultants, including their fees, stock-based compensation and related travel expenses; ● costs of laboratory supplies and acquiring, developing and manufacturing preclinical and clinical trial materials; ● expenses related to compliance with regulatory requirements; and ● facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of fa

filing / May 13, 2026 / receipt

● our headcount growth and associated costs as we expand our business operations and our research and development activities; and

filing / May 13, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may affect our ability to generate revenue, attain or maintain profitability, or commercialize our product candidates.

filing / May 13, 2026 / receipt

If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and product candidates outside of the United States, which could limit our growth potential and increase our development costs.

filing / May 13, 2026 / receipt

A primary trend in the healthcare industry in the United States and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.

filing / May 13, 2026 / receipt